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ABSTRACT
Bronchial artery embolization (BAE) is the mainstay treatment for massive haemoptysis. Herein we briefly discuss the 
tips and tricks of super-selective embolization of bronchial artery using N-butyl-2 cyanoacrylate (NBCA).  Based on 
our experience, this technique produces a better resolution and exhibit high non- recurrence rate in the treatment of 
massive haemoptysis.
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INTRODUCTION
Massive recurrent haemoptysis is a devastating 
complication of airway disease that may lead to death. 
The diseases that could lead to haemoptysis differs; 
depending on the geographic location, the climates, 
associate local endemic pulmonary disease, genetic 
factors and even time of presentation are important. 
Our institution is located in Southeast Asia known for its 
stable tropical warm humid climate throughout the year. 
Thus, the tropical climate-related respiratory diseases 
are not uncommon. From our observation; we noticed 
that the main culprit for haemoptysis in our institution is 
bronchiectasis secondary to post-primary TB infection. 
Unfortunately, there is no local data published to 
support our claim. 
We are inclined to the idea that the main cause of death 
in-patient with massive haemoptysis is ironically due 
to asphyxiation rather than haemodynamic instability, 
hence, it is important to control the haemoptysis in a 
patient who is unable to protect their airways; even 
though the amount of expectorated blood is small 
(1). Protection of the non-affected site from the blood 
pooling is necessary during massive haemoptysis. 
There is no reliable sign to predict impending 
asphyxiation or to anticipate transformation of mild 
benign haemoptysis to a massive live threatening 
haemoptysis. It is based on this reason; a suspected 
massive haemoptysis patient ideally should be placed 
in the acute bay setting such as High Dependency 
Unit (HDU) whereby the equipment and the personnel 
experienced in fluid and airway resuscitation are readily 
available. A multidisciplinary approach involving the 
intensivist, cardiothoracic surgeon, interventional 
respiratory physician and the interventional radiologist is 
probably the best practice in managing life-threatening 
haemoptysis. In our experience, the ability of a patient 
to cough up blood and clearing up the airway is one 
important good prognostic criteria. There is a challenge 
to manage an ill patient with existing lung disease 
presented concomitantly with difficulty of breathing. It is 
difficult to identify whether the deteriorating respiratory 
condition is due to either worsening primary lung 
disease or blood “flooding” the lower airways causing 
shortness of breath. In addition to the problem, there 
is no universal consensus on the definition of massive 
haemoptysis for the clinician to react. Several authors 
have suggested the amount of blood loss is the main 
criteria to define the severity of haemoptysis. The basis 
of this definition is usually based on the flow rate of 
bleeding per unit time. The expectorated amount of 
blood to be labelled as massive haemoptysis ranging from 
100ml /24hr to 1000mls/24 hr (2). Criteria based on pre-
existing respiratory distress, current respiratory status, 
the magnitude of exporated blood and haemodynamic 
instability have been suggested to be more inclusive (3). 
Hence, Ibrahim W H (2010) suggested the term “life-
threatening haemoptysis” that is probably more accurate 
than the previously accepted “massive haemoptysis” (3). 
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The treatment option is much depended on institutional 
preference. In our institutional practice, the first line 
treatment for massive recurrent haemoptysis is always 
bronchial artery embolization (BAE) due to its highly 
successful rate with relatively low complication rate (4). 
As for the interventional radiologist, there are many 
choices of embolic material in the market. Two popular 
embolic materials for BAE are polyvinyl alcohol (PVA) 
particles and acrylic adhesive called popularly called 
NBCA (N-butyl-2 cyanoacrylate, Histoacryl Blue®; 
B. Braun, Melgungen, Germany). Recent evidence 
suggested that the NBCA is superior to other popular 
embolic material (Fig 1). Woo et al (2013) suggested 
that NBCA mixture has low recanalization rate and is 
the best option to treat haemoptysis in bronchiectasis 
patients. In their study, the complication rate of the 
polyvinyl alcohol (PVA) versus NBCA mixture is similar; 
BAE with NBCA mixture is more effective controlling 
haemoptysis caused by bronchiectasis (5).
Yoo et al suggested that the non-recurrence rate after 
embolization using NBCA mixture in the first year is as 
high as 91.4% and non -recurrence rate within 5 years is 
up to 56.8%. The complication occurred is mainly chest 
wall pain (6). Ikoma et al (2011) suggested that the usage 
of NBCA does not cause major damage to the bronchial 
wall or to the pulmonary parenchyma as previously 
thought (7). Polymerization of NBCA occurs immediately 
once the acrylic polymers adhesive is in contact with 
hydroxyl ions in the blood or any ionic material in 
the targeted area. This polymerization complex later 
will produce chronic inflammatory process within the 
vessels wall that delaying recanalization to occur. NBCA 
usage is shown to have a lower tendency of a recurrent 
haemoptysis as compared to other embolic agents (5, 
8, 9).
Embolization coil is relatively safer in cases whereby 
the communication between the diseased artery and the 
spinal artery has not been completely rule out, or in a 
fast high-velocity arteriovenous fistulas communication. 
It is commonly used after the PVA embolization to 
completely plug off the intended artery. Worth to 
mention, coils sometimes are used to reduce the velocity 
of the blood flow of the artery of interest prior to NBCA 
administration to prevent distant venous embolization 
or migration of the NBCA complex.
MATERIAL AND METHODS
Our institution is a referral centre for cardiac and 
respiratory cases for the nation and most of our BAE cases 
are referrals from other hospitals. As a standard practice, 
the patient for bronchial artery embolization will be 
admitted a day prior to the procedure; in the care of 
the primary team either internal medicine or respiratory 
team. The procedure and its risks are explained to the 
patient including the first-degree relative. During the 
session, we would emphasise on the most devastating 
event first such as risks of stroke (in the event of venous 
shunting, arterial communication) or risks of embolic 
injury to the spinal cord through connection with the 
anterior spinal artery.  Written informed consent will be 
taken in the ward and in the interventional suite. There is 
no need for premedication prior to the procedure. Basic 
blood investigation is routinely done such as blood 
profile and coagulation profile. It is an advantage if CT 
angiography images are available due to the opportunity 
to evaluate the anatomical structure of the bronchial 
artery as the incidence of an accessory bronchial artery 
is approximately 36% (10).
 We prefer the patient to be awake during the procedure 
if the patient is stable. In a haemodynamically or 
respiratory unstable patient; the embolization procedure 
will be done under general anaesthesia. Generally, a 
double lumen endotracheal tube intubation is preferred 
with the intention to protect the normal airway from 
spill over from the abnormal side of the lung, or in some 
centre, a large size of endotracheal tube (ETT) is used 
(more than 8mm diameter) due to the anticipation of 
concurrent bronchoscopy. Right femoral puncture is 
preferred. The standard femoral arterial sheath will be 
used. The preferred catheter of choice is Cobra catheter. 
Cobra C2 (catheter shape) for a male due to larger angle 
curvature of its tip making this type of catheter easier to 
manoeuvre in the larger calibre thoracic aorta than C1; 
however, we may change the type of catheter accordingly. 
The amount of contrast used to search for the ostium is 
significantly less by using only 3-5 ml of diluted contrast 
media per digital subtraction angiography (DSA) run. 
It is important for the operator applies pressure at the 
injector of the syringe. This is to prevent backflow of the 
arterial blood into the syringe and further contaminate 
the syringe that is prefilled with diluted contrast media. 
Once the ostium is identified; a few arterial runs will 
be commenced and arteriograms acquired using digital 
subtraction angiography technique. It is important to 
identify any venous shunting (fistulous communication) 
is present and to rule out any formation of the anterior 
spinal artery (The artery of adamkewiz- name after Albert 
Wojciech Adamkiewicz) that may have originated from 
the bronchial artery or the intercostal bronchial artery. 
The anterior spinal artery that is originated from the 
intercostal bronchial artery (ICBA) is rare at approximately 
5% incidence (11). It is important to carefully look 
for this anatomical variant by doing super-selective 
angiography to the targeted vessel using microcatheter 
or making sure that there is no artery going to the medial 
side and give a faint “hairpin appearance”. It is important 
to note any presence of extremely rare arterial-arterial 
communication. Communication between the bronchial 
artery - subclavian artery and bronchial artery - right 
coronary artery is well documented in the literature. 
(12, 13). We had an experience of causing iatrogenic 
posterior circulation infarction during BAE. The presence 
of these anatomical variants may complicate treatment. 
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Figure 1: DSA image showing faint contrast opacification within the 
previously embolized left internal thoracic artery using PVA and coil. 
This is suggestive of recanalization of the artery (arrowhead). An 
endovascular coil within the left internal thoracic artery (arrow).
RESULTS
To determine the nature of the vasculature, oblique or 
cranio-caudal angulations of tube projection, multiple 
arterial DSA run with magnification view are suggested. 
The clues for diagnosing abnormal vessels are; the 
abnormal bronchial artery is usually dilated, especially 
at the proximal part, the abnormal artery is usually 
tortuous, the presence of corkscrew appearance at the 
mid and distal bronchial arteries, and abnormal blushing 
or hyperaemia of the lung parenchyma. It is very rare 
to detect an active extravasation of contrast into the 
alveolar/bronchus during the procedure.
We use multipurpose microcatheter; (Progreat 2.7 Fr- 
0.90mm, Terumo or ASAHI Masters PARKWAY HF 
KIT 2.8 Fr- 0.88mm) as the microcatheter of choice 
to super-selectively catheterize the bronchial artery 
and other non-bronchial thoracic arteries. We have 
experienced few cases of recanalization occurred after 
PVA and coils deployment (Figure 1). It is for this reason 
we have adopted a new strategy to use acrylic glue for 
embolization. We believe that chronic inflammatory 
process changes and scarred tissue are better embolized 
using NBCA.  The main constraint for NBCA usage is 
a high cost incurred due to more expensive lipiodol 
(ethiodized poppy seed oil) as opposed to PVA. The 
other reason is the micro-catheter that has been used 
for the initial embolization will be discarded due to glue 
material residue within the micro-catheter lumen.
DISCUSSION
Once the bronchial artery is selectively catheterized, it 
is best to assess the dynamic flow by injecting a small 
amount of contrast under fluoroscopy. The decision to 
use glue (NBCA) or other embolic material is made after 
acquiring this information. If the patient is intubated, it 
is an opportunity to ask the anaesthetist to do a “breath-
hold” technique to pause the ventilation. The aim is 
to minimize the motion artefact occurred during the 
arterial run. If the glue material usage has been chosen, 
the concentration of the glue is based on the blood flow, 
wideness area to be blocked and the presence of venous 
shunting (Figure 2). The standard concentration of NBCA 
mixture in our institution is about 25-50% dilution using 
ethiodized poppy seed oil (lipiodol) as the diluent. 
Adding more diluent can prolong the polymerization 
time. We had an experienced using 90% NBCA in due 
to large venous shunting into the pulmonary veins. The 
most important thing before administration of NBCA 
mixture is the knowledge about the arterial velocity, 
prediction of NBCA polymerization time and the 
Figure 2: Pre-embolization DSA image of the abnormal bronchial 
vessels with early venous appearance (white arrows).
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Figure 3: A – pre-embolization DSA image of the left bronchial artery.  B - Post embolization image showing glue cast within the 
embolized left bronchial artery (arrows).
polymerization of NBCA, such the operators need to 
change a new set latex hand glove and put another layer 
of clean dry cloth to prevent accidentally mixing ionic 
fluid into the NBCA mix. We used Dextrose 5% to wash 
out any blood product in the micro-catheter lumen and 
hub. We also soaked our glove with dextrose as one of 
precautionary action. 
Under fluoroscopy control; staggered injection by 
adequately squirting about 0.2 ml in up to every 2-3 
seconds is recommended, however, the operators 
must know and in real time control the injection rate 
according to the ever-changing dynamicity of the blood 
flow. The blood flow will be slower once the injection 
is commenced. It is important to assess for the proximal 
reflux all the time.  Injection is stopped once stagnation 
of opaque embolic material is seen at the region of 
interest (Figure 3). Removal of the micro-catheter is done 
immediately to prevent micro-catheter adherence to the 
arterial wall. The radio-opacity of NBCA mixture is less 
if the Lipiodol concentration is < 50%. In a large area of 
lung parenchymal involvement; a staged embolization 
can be organized. A repeat embolization will be done at 
a later date usually within 1-3 month depending on the 
severity of the symptoms.
It is permissible to block the entire right bronchial 
artery as long as it is not supplying the anterior spinal 
arteries (Figure 4).  It is based on the fact that the lung 
parenchyma has dual lung arterial supply. The non-
bronchial arteries that are worth to be investigated 
are internal mammary, subclavian, lateral thoracic 
and intercostal arteries. Recently, a triaxial system has 
been developed and tried in Japan harbouring 92 % 
cessation of haemoptysis. The system used 1.9 Fr no 
taper microcatheter, 2.7 Fr microcatheter and lastly 4 Fr 
Figure 4: Post embolization image- Glue/NBCA 
cast formation within the right distal intercostal
bronchial artery (arrows)
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as guiding catheter into the bronchial artery ostium (14). 
The NBCA will be injected through 1.9Fr microcatheter, 
and later after the withdrawal of 1.9Fr microcatheter, the 
2.7 fr microcatheter will be used for confirmatory highly 
selective angiography run to the embolized artery.
The immediate usual complication is chest wall pain, 
and up to 89% has been reported (15). From our 
experience, the chest pain is usually mild and involved 
the anterior wall of the chest depending on the place of 
the embolization. Most of our patients do not require 
heavy painkillers or sedation.
CONCLUSION
Super-selective embolization of bronchial artery 
using NBCA is a safe, quick and reliable method for a 
successful treatment of massive haemoptysis.
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